{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T13:09:39Z","timestamp":1785244179452,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T00:00:00Z","timestamp":1770508800000},"content-version":"am","delay-in-days":372,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","academicradiology.org","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Academic Radiology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.acra.2024.08.043","type":"journal-article","created":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T11:36:51Z","timestamp":1725277011000},"page":"1026-1035","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["18F-FDG-PET\/CT Uptake by Noncancerous Lung as a Predictor of Interstitial Lung Disease Induced by Immune Checkpoint Inhibitors"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0006-9089","authenticated-orcid":false,"given":"Motohiko","family":"Yamazaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0041-6981","authenticated-orcid":false,"given":"Satoshi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Tominaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Yagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiro","family":"Yanagimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Arita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Ohtsubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Nozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Saida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rie","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.acra.2024.08.043_bib1","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.acra.2024.08.043_bib2","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.acra.2024.08.043_bib3","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.acra.2024.08.043_bib4","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.acra.2024.08.043_bib5","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"issue":"10212","key":"10.1016\/j.acra.2024.08.043_bib6","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.acra.2024.08.043_bib7","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus Ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.acra.2024.08.043_bib8","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.acra.2024.08.043_bib9","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Daniel","year":"2018","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.acra.2024.08.043_bib10","doi-asserted-by":"crossref","first-page":"790","DOI":"10.3390\/biomedicines10040790","article-title":"Review of immune-related adverse events (irAEs) in non-small-cell lung cancer (NSCLC)-their incidence, management, multiorgan irAEs, and rechallenge","volume":"10","author":"Vaddepally","year":"2022","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.acra.2024.08.043_bib11","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"10.1016\/j.acra.2024.08.043_bib12","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.chest.2017.04.177","article-title":"Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials","volume":"152","author":"Khunger","year":"2017","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.acra.2024.08.043_bib13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13244-021-01153-9","article-title":"A review on advances in 18F-FDG PET\/CT radiomics standardisation and application in lung disease management","volume":"13","author":"Anan","year":"2022","journal-title":"Insights Imaging"},{"issue":"6","key":"10.1016\/j.acra.2024.08.043_bib14","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/j.chest.2021.12.656","article-title":"Clinical outcomes of immune checkpoint inhibitor therapy in patients with advanced non-small cell lung cancer and preexisting interstitial lung diseases: a systematic review and meta-analysis","volume":"161","author":"Zhang","year":"2022","journal-title":"Chest"},{"key":"10.1016\/j.acra.2024.08.043_bib15","series-title":"Common terminology criteria for adverse events (CTCAE)","author":"U.S. Department of Health and Human Services","year":"2024"},{"issue":"5","key":"10.1016\/j.acra.2024.08.043_bib16","article-title":"TotalSegmentator: robust segmentation of 104 anatomic structures in CT images","volume":"5","author":"Wasserthal","year":"2023","journal-title":"Radiol Artif Intell"},{"issue":"9","key":"10.1016\/j.acra.2024.08.043_bib17","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.mri.2012.05.001","article-title":"3D slicer as an image computing platform for the quantitative imaging network","volume":"30","author":"Fedorov","year":"2012","journal-title":"Magn Reson Imaging"},{"issue":"6","key":"10.1016\/j.acra.2024.08.043_bib18","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000000531","article-title":"The applications of corrected standardized uptake values in the diagnosis of peripheral lung lesions","volume":"94","author":"Ming","year":"2015","journal-title":"Medicine"},{"issue":"6","key":"10.1016\/j.acra.2024.08.043_bib19","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.2214\/AJR.19.21376","article-title":"Prognostic value of the volumetric parameters of dual-time-point 18F-FDG PET\/CT in non-small cell lung cancer treated with definitive radiation therapy","volume":"213","author":"Okazaki","year":"2019","journal-title":"Am J Roentgenol"},{"issue":"1","key":"10.1016\/j.acra.2024.08.043_bib20","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1148\/radiol.2021204367","article-title":"Interstitial lung abnormalities: state of the art","volume":"301","author":"Hata","year":"2021","journal-title":"Radiology"},{"issue":"11","key":"10.1016\/j.acra.2024.08.043_bib21","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.22906","article-title":"Association of preexisting interstitial lung abnormalities with immune checkpoint inhibitor-induced interstitial lung disease among patients with nonlung cancers","volume":"3","author":"Shimoji","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.acra.2024.08.043_bib22","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2307\/2529310","article-title":"The measurement of observer agreement for categorical data","volume":"33","author":"Landis","year":"1977","journal-title":"Biometrics"},{"issue":"1","key":"10.1016\/j.acra.2024.08.043_bib23","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-15964-3","article-title":"Prospective assessment using 18F-FDG PET\/CT as a novel predictor for early response to PD-1 blockade in non-small-cell lung cancer","volume":"12","author":"Yamaguchi","year":"2022","journal-title":"Sci Rep"},{"issue":"9","key":"10.1016\/j.acra.2024.08.043_bib24","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.2967\/jnumed.116.188839","article-title":"Prediction of response to immune checkpoint inhibitor therapy using early-time-point 18F-FDG PET\/CT imaging in patients with advanced melanoma","volume":"58","author":"Cho","year":"2017","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1016\/j.acra.2024.08.043_bib25","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.acra.2024.08.043_bib26","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1007\/s00262-021-02855-1","article-title":"Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors","volume":"70","author":"Tyan","year":"2021","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"10.1016\/j.acra.2024.08.043_bib27","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.21037\/jtd-22-93","article-title":"Immune checkpoint inhibitor-related interstitial lung disease in patients with advanced non-small cell lung cancer: systematic review of characteristics, incidence, risk factors, and management","volume":"14","author":"Kim","year":"2022","journal-title":"J Thorac Dis"},{"issue":"5","key":"10.1016\/j.acra.2024.08.043_bib28","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1158\/1078-0432.CCR-18-2795","article-title":"Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-based immunotherapy","volume":"25","author":"Lim","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.acra.2024.08.043_bib29","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40425-015-0081-1","article-title":"Baseline circulating IL-17 predicts toxicity while TGF-\u03b21 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma","volume":"3","author":"Tarhini","year":"2015","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.acra.2024.08.043_bib30","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1080\/0284186X.2017.1406668","article-title":"Interleukin-6 as one of the potential mediators of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint blockade: evidence from a case report","volume":"57","author":"Naqash","year":"2018","journal-title":"Acta Oncol"},{"issue":"3","key":"10.1016\/j.acra.2024.08.043_bib31","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.jtcvs.2019.07.100","article-title":"Association between F-18 fluorodeoxyglucose uptake of noncancerous lung area and acute exacerbation of interstitial pneumonia in patients with lung cancer after resection","volume":"159","author":"Yamamichi","year":"2020","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"4","key":"10.1016\/j.acra.2024.08.043_bib32","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s10147-019-01584-x","article-title":"Predictive value of 18F-FDG PET\/CT for acute exacerbation of interstitial lung disease in patients with lung cancer and interstitial lung disease treated with chemotherapy","volume":"25","author":"Akaike","year":"2020","journal-title":"Int J Clin Oncol"},{"issue":"10","key":"10.1016\/j.acra.2024.08.043_bib33","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.21037\/jtd-22-604","article-title":"Clinical impact of SUVmax of interstitial lesions in lung cancer patients with interstitial lung disease who underwent pulmonary resection","volume":"14","author":"Akaike","year":"2022","journal-title":"J Thorac Dis"},{"issue":"5","key":"10.1016\/j.acra.2024.08.043_bib34","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1007\/s00259-017-3917-8","article-title":"Pulmonary 18F-FDG uptake helps refine current risk stratification in idiopathic pulmonary fibrosis (IPF)","volume":"45","author":"Win","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1016\/j.acra.2024.08.043_bib35","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1148\/radiol.2019191882","article-title":"The QIBA profile for FDG PET\/CT as an imaging biomarker measuring response to cancer therapy","volume":"294","author":"Kinahan","year":"2020","journal-title":"Radiology"},{"issue":"12","key":"10.1016\/j.acra.2024.08.043_bib36","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.2967\/jnumed.120.244780","article-title":"Consensus recommendations on the use of 18F-FDG PET\/CT in lung disease","volume":"61","author":"Chen","year":"2020","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.acra.2024.08.043_bib37","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00259-011-1934-6","article-title":"Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer","volume":"39","author":"Liao","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.acra.2024.08.043_bib38","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1093\/oncolo\/oyad187","article-title":"Pre-existing interstitial lung abnormalities and immune checkpoint inhibitor-related pneumonitis in solid tumors: a retrospective analysis","volume":"29","author":"Horiuchi","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.acra.2024.08.043_bib39","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.lungcan.2018.10.001","article-title":"Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: a\u00a0retrospective analysis","volume":"125","author":"Yamaguchi","year":"2018","journal-title":"Lung Cancer"},{"issue":"5","key":"10.1016\/j.acra.2024.08.043_bib40","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.resinv.2019.05.002","article-title":"Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer","volume":"57","author":"Nakanishi","year":"2019","journal-title":"Respir Investig"}],"container-title":["Academic Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1076633224006068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1076633224006068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T07:30:22Z","timestamp":1738999822000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1076633224006068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1076633224006068"],"URL":"https:\/\/doi.org\/10.1016\/j.acra.2024.08.043","relation":{},"ISSN":["1076-6332"],"issn-type":[{"value":"1076-6332","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"18F-FDG-PET\/CT Uptake by Noncancerous Lung as a Predictor of Interstitial Lung Disease Induced by Immune Checkpoint Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Academic Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acra.2024.08.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Association of Academic Radiology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}